Skip to main content
Erschienen in: Familial Cancer 3/2008

01.09.2008

Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models

verfasst von: Hassan Roudgari, Zosia H. Miedzybrodzka, Neva E. Haites

Erschienen in: Familial Cancer | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Background Accurate risk assessment is essential to genetic counselling for a family history of cancer. Several empiric and computer-based risk assessment models have been developed to estimate a counselee’s probability of being a carrier of mutation in BRCA1 and/or 2 genes, and to predict the risk of developing breast cancer. The COS model was developed from the better-known BRCAPro model to estimate risk of carriage of BRCA1 or 2 mutation. The COS model remains to be validated in a population discrete from that used for its development. Methods Four probability estimation models including COS, Manchester scoring system (MSS), BOADICEA and Tyrer–Cuzick (T–C) were applied to 275 Scottish families tested for BRCA1/2 mutations ascertained through regional genetics centres to ascertain models’ sensitivity, specificity and accuracy. A subset of 130 families from Grampian (North and Northeast Scotland) was used to assess the models’ ability to estimate the prevalence of BRCA1/2 mutation carriers. Sensitivity, specificity and ROC plots were used to ascertain models’ individual performance, in terms of number of cancer cases, type of cancer and age of diagnosis of breast cancer. Results The COS and MSS models demonstrated the greatest sensitivities and area under ROC curves for the majority of family structures. They also showed the highest sensitivities (91–92%) and AUCs (76–78%) for the entire dataset overall. However, BOADICEA and T–C had the highest specificities for the majority of the family structures. BOADICEA and T–C generated the best estimates for the prevalence of mutations in the population; BOADICEA was more accurate for BRCA1 and T–C for BRCA2. Conclusion The COS and MSS models are the most effective models for use in clinical practice to select families for mutation analysis, but BOADICEA and T–C are more accurate for estimating mutation prevalence within a population.
Literatur
1.
Zurück zum Zitat Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM (2003) Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. Med J Aust 178(2):77–81PubMed Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM (2003) Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. Med J Aust 178(2):77–81PubMed
2.
Zurück zum Zitat Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA (2003) Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138(12):1323–1328PubMedCrossRef Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA (2003) Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 138(12):1323–1328PubMedCrossRef
3.
Zurück zum Zitat Henriksson K, Olsson H, Kristoffersson U (2004) The need for oncogenetic counseling—ten years’ experience of a regional oncogenetic clinic. Acta Oncologica 43(7):637–649PubMedCrossRef Henriksson K, Olsson H, Kristoffersson U (2004) The need for oncogenetic counseling—ten years’ experience of a regional oncogenetic clinic. Acta Oncologica 43(7):637–649PubMedCrossRef
4.
Zurück zum Zitat Contegiacomo A, Pensabene M, Capuano I, Tauchmanova L, Federico M, Turchetti D, Cortesi L, Marchetti P, Ricevuto E, Cianci G, Venuta S, Barbieri V, Silingardi V (2004) An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol 15(5):726–732PubMedCrossRef Contegiacomo A, Pensabene M, Capuano I, Tauchmanova L, Federico M, Turchetti D, Cortesi L, Marchetti P, Ricevuto E, Cianci G, Venuta S, Barbieri V, Silingardi V (2004) An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol 15(5):726–732PubMedCrossRef
5.
Zurück zum Zitat Iredale R, Elwyn G, Edwards A, Gray J (2007) Attitudes of genetic clinicians in Wales to the future development of cancer genetic services. J Eval Clin Pract 13(1):86–89PubMedCrossRef Iredale R, Elwyn G, Edwards A, Gray J (2007) Attitudes of genetic clinicians in Wales to the future development of cancer genetic services. J Eval Clin Pract 13(1):86–89PubMedCrossRef
6.
Zurück zum Zitat Schlich-Bakker KJ, ten Kroode HFJ, Ausems MGEM (2006) A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 62(1):13–20PubMedCrossRef Schlich-Bakker KJ, ten Kroode HFJ, Ausems MGEM (2006) A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 62(1):13–20PubMedCrossRef
7.
Zurück zum Zitat Brown P (2005) Risk assessment: controversies and management of moderate- to high-risk individuals. Breast J 11(s1):S11–S19PubMedCrossRef Brown P (2005) Risk assessment: controversies and management of moderate- to high-risk individuals. Breast J 11(s1):S11–S19PubMedCrossRef
8.
Zurück zum Zitat Claus EB, Risch N, Thompson WD (1994) Autosomal-dominant inheritance of early-onset breast-cancer—implications for risk prediction. Cancer 73(3):643–651PubMedCrossRef Claus EB, Risch N, Thompson WD (1994) Autosomal-dominant inheritance of early-onset breast-cancer—implications for risk prediction. Cancer 73(3):643–651PubMedCrossRef
9.
Zurück zum Zitat Murday V (1994) Genetic counselling in the cancer family clinic. Eur J Cancer 30A(13):2012–2015PubMedCrossRef Murday V (1994) Genetic counselling in the cancer family clinic. Eur J Cancer 30A(13):2012–2015PubMedCrossRef
10.
Zurück zum Zitat Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Haites N, Milner B, Allan L, Ponder BAJ, Peto J, Smith S, Stratton M, Lenoir GM, Feunteun J, Lynch H, Arason A, Barkardottir R, Egilsson V, Black DM, Kelsell D, Spurr N, Devilee P, Cornelisse CJ, Varsen H, Birch JM, Skolnick M, Santibanezkoref MS, Teare D, Steel M, Porter D, Cohen BB, Carothers A, Smyth E, Weber B, Newbold B, Boehnke M, Collins FS, Cannonalbright LA, Goldgar D (1994) Risks of cancer in Brca1—mutation carriers. Lancet 343(8899):692–695PubMedCrossRef Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Haites N, Milner B, Allan L, Ponder BAJ, Peto J, Smith S, Stratton M, Lenoir GM, Feunteun J, Lynch H, Arason A, Barkardottir R, Egilsson V, Black DM, Kelsell D, Spurr N, Devilee P, Cornelisse CJ, Varsen H, Birch JM, Skolnick M, Santibanezkoref MS, Teare D, Steel M, Porter D, Cohen BB, Carothers A, Smyth E, Weber B, Newbold B, Boehnke M, Collins FS, Cannonalbright LA, Goldgar D (1994) Risks of cancer in Brca1—mutation carriers. Lancet 343(8899):692–695PubMedCrossRef
11.
Zurück zum Zitat Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCrossRef Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158PubMedCrossRef
12.
Zurück zum Zitat Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93(23):1811–1817PubMedCrossRef Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93(23):1811–1817PubMedCrossRef
13.
Zurück zum Zitat Antoniou AC, Pharoah PPD, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580–1590PubMed Antoniou AC, Pharoah PPD, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580–1590PubMed
14.
Zurück zum Zitat Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480PubMedCrossRef Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480PubMedCrossRef
15.
Zurück zum Zitat Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRef Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130PubMedCrossRef
16.
Zurück zum Zitat Kang HH, Williams R, Leary J, Ringland C, Kirk J, Ward R (2006) Evaluation of models to predict BRCA germline mutations. Br J Cancer 95(7):914–920PubMedCrossRef Kang HH, Williams R, Leary J, Ringland C, Kirk J, Ward R (2006) Evaluation of models to predict BRCA germline mutations. Br J Cancer 95(7):914–920PubMedCrossRef
17.
Zurück zum Zitat Claus EB, Risch N, Thompson WD (1991) Genetic-analysis of breast—cancer in the cancer and steroid-hormone study. Am J Hum Genet 48(2):232–242PubMed Claus EB, Risch N, Thompson WD (1991) Genetic-analysis of breast—cancer in the cancer and steroid-hormone study. Am J Hum Genet 48(2):232–242PubMed
18.
Zurück zum Zitat Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814PubMedCrossRef Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814PubMedCrossRef
19.
Zurück zum Zitat Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905PubMedCrossRef Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905PubMedCrossRef
20.
Zurück zum Zitat Evans DGR, Lalloo F, Wallace A, Rahman N (2005) Update on the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 42(7):e39PubMedCrossRef Evans DGR, Lalloo F, Wallace A, Rahman N (2005) Update on the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 42(7):e39PubMedCrossRef
21.
Zurück zum Zitat Roudgari H, Masson LF, Haites NE. Information recovery in cancer families: value for risk estimations. Fam Cancer 23/May/2007 (online version) Roudgari H, Masson LF, Haites NE. Information recovery in cancer families: value for risk estimations. Fam Cancer 23/May/2007 (online version)
22.
Zurück zum Zitat American Society of Clinical Oncology (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730–1736 American Society of Clinical Oncology (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730–1736
23.
Zurück zum Zitat American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397–2406CrossRef American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21(12):2397–2406CrossRef
24.
Zurück zum Zitat Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561–577 (published erratum appears in Clin Chem 1993 Aug; 39(8):1589)PubMed Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561–577 (published erratum appears in Clin Chem 1993 Aug; 39(8):1589)PubMed
25.
Zurück zum Zitat Dujardin B, Vandenende J, Vangompel A, Unger JP, Vanderstuyft P (1994) Likelihood ratios—a real improvement for clinical decision-making. Eur J Epidemiol 10(1):29–36PubMedCrossRef Dujardin B, Vandenende J, Vangompel A, Unger JP, Vanderstuyft P (1994) Likelihood ratios—a real improvement for clinical decision-making. Eur J Epidemiol 10(1):29–36PubMedCrossRef
26.
Zurück zum Zitat Moons KGM, Vanes GA, Deckers JW, Habbema JDF, Grobbee DE (1997) Limitations of sensitivity, specificity, likelihood ratio, and Bayes’ theorem in assessing diagnostic probabilities: a clinical example. Epidemiology 8(1):12–17PubMedCrossRef Moons KGM, Vanes GA, Deckers JW, Habbema JDF, Grobbee DE (1997) Limitations of sensitivity, specificity, likelihood ratio, and Bayes’ theorem in assessing diagnostic probabilities: a clinical example. Epidemiology 8(1):12–17PubMedCrossRef
27.
Zurück zum Zitat Obuchowski NA, Lieber ML, Wians FH Jr (2004) ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 50(7):1118–1125PubMedCrossRef Obuchowski NA, Lieber ML, Wians FH Jr (2004) ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 50(7):1118–1125PubMedCrossRef
28.
Zurück zum Zitat Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. JNCI Cancer Spectr 94(11):844–851 Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. JNCI Cancer Spectr 94(11):844–851
29.
Zurück zum Zitat Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. JNCI Cancer Spectr 91(11):943–949CrossRef Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. JNCI Cancer Spectr 91(11):943–949CrossRef
30.
Zurück zum Zitat Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B (2000) The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia 5(2):139–163PubMedCrossRef Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B (2000) The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia 5(2):139–163PubMedCrossRef
31.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490PubMedCrossRef
32.
Zurück zum Zitat Barcenas CH, Hosain GMM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI (2006) Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24(3):354–360PubMedCrossRef Barcenas CH, Hosain GMM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI (2006) Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24(3):354–360PubMedCrossRef
33.
Zurück zum Zitat Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56(1):265–271PubMed Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56(1):265–271PubMed
34.
Zurück zum Zitat Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRef Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRef
35.
Zurück zum Zitat Anderson H, Bladstrom A, Olsson H, Moller TR (2000) Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 152(12):1154–1163PubMedCrossRef Anderson H, Bladstrom A, Olsson H, Moller TR (2000) Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 152(12):1154–1163PubMedCrossRef
Metadaten
Titel
Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models
verfasst von
Hassan Roudgari
Zosia H. Miedzybrodzka
Neva E. Haites
Publikationsdatum
01.09.2008
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2008
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-007-9176-2

Weitere Artikel der Ausgabe 3/2008

Familial Cancer 3/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.